Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano, TX 75024
United States
972 865 2219
https://www.reatapharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 321
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. J. Warren Huff | Chairman, CEO & Sec. | 1.11M | 無 | 1954 |
| Mr. Manmeet Singh Soni | COO, CFO & Pres | 1.02M | 無 | 1978 |
| Mr. Michael D. Wortley | Exec. VP and Chief Legal & Compliance Officer | 773.06k | 無 | 1948 |
| Dr. Colin J. Meyer M.D. | Exec. VP & Chief Innovation Officer | 842.4k | 無 | 1979 |
| Ms. Dawn Carter Bir | Exec. VP & Chief Commercial Officer | 652.39k | 無 | 1971 |
| Mr. Bhaskar Anand | Sr. VP & Chief Accounting Officer | 無 | 無 | 1978 |
| Dr. W. Christian Wigley Ph.D. | Sr. VP & Chief Scientific Officer | 無 | 無 | 無 |
| Mr. Steve Harman | Sr. VP & Chief HR Officer | 無 | 無 | 無 |
| Dr. Samina Khan M.D. | Chief Medical Officer & Sr. VP | 無 | 無 | 1965 |
| Mr. Dakota Gallivan | VP & Chief Healthcare Compliance Officer | 無 | 無 | 無 |
描述
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. As of September 26, 2023, Reata Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
公司管治
截至 2023年9月1日 止，Reata Pharmaceuticals, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：2；董事會：9；股東權利：10；現金賠償：10。
